Nurix Therapeutics' stock surged 5.90% during intraday trading on Thursday, reflecting strong investor confidence in the biotechnology company.
The price increase follows a series of positive analyst actions, including price target raises and maintained buy ratings from multiple firms. H.C. Wainwright increased its target price to $32 from $31, Stifel raised its target to $35 from $33, and RBC lifted its target to $30 from $28, all while maintaining bullish ratings. Additionally, Wells Fargo maintained an Overweight rating and BTIG sustained its positive outlook with a $30 price target.